JP2005531614A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005531614A5 JP2005531614A5 JP2004512791A JP2004512791A JP2005531614A5 JP 2005531614 A5 JP2005531614 A5 JP 2005531614A5 JP 2004512791 A JP2004512791 A JP 2004512791A JP 2004512791 A JP2004512791 A JP 2004512791A JP 2005531614 A5 JP2005531614 A5 JP 2005531614A5
- Authority
- JP
- Japan
- Prior art keywords
- pora
- vesicle
- meningococcal
- deficient
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 claims 11
- 230000002950 deficient Effects 0.000 claims 10
- 229960005486 vaccine Drugs 0.000 claims 7
- 241000588653 Neisseria Species 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000037941 meningococcal disease Diseases 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 241000287798 Neisseria meningitidis CU385 Species 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0213622.4A GB0213622D0 (en) | 2002-06-13 | 2002-06-13 | Vaccine Corporation |
| PCT/EP2003/006094 WO2003105890A2 (en) | 2002-06-13 | 2003-06-10 | Vaccine composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005531614A JP2005531614A (ja) | 2005-10-20 |
| JP2005531614A5 true JP2005531614A5 (enExample) | 2006-07-27 |
Family
ID=9938532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004512791A Pending JP2005531614A (ja) | 2002-06-13 | 2003-06-10 | ワクチン組成物 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20060110412A1 (enExample) |
| EP (1) | EP1565211A2 (enExample) |
| JP (1) | JP2005531614A (enExample) |
| KR (1) | KR20050049431A (enExample) |
| CN (1) | CN100387298C (enExample) |
| AR (1) | AR040204A1 (enExample) |
| AU (1) | AU2003236734A1 (enExample) |
| BR (1) | BR0311777A (enExample) |
| CA (1) | CA2488782A1 (enExample) |
| CL (1) | CL2003001192A1 (enExample) |
| CU (1) | CU23552A1 (enExample) |
| GB (1) | GB0213622D0 (enExample) |
| MX (1) | MXPA04012568A (enExample) |
| NO (1) | NO20050132L (enExample) |
| NZ (1) | NZ560766A (enExample) |
| PE (1) | PE20040562A1 (enExample) |
| RU (1) | RU2005100509A (enExample) |
| UY (1) | UY27843A1 (enExample) |
| WO (1) | WO2003105890A2 (enExample) |
| ZA (1) | ZA200409547B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030024811A (ko) | 2000-07-27 | 2003-03-26 | 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 | 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신 |
| GB2414667A (en) * | 2004-06-03 | 2005-12-07 | Isis Innovation | Vaccine compositions of N. meningitidis PorA and FetA antigens |
| GB0419627D0 (en) * | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| BRPI0607374B8 (pt) | 2005-01-27 | 2021-05-25 | Childrens Hospital & Res Center At Oakland | vacinas de vesículas baseadas em gna1870 para proteção de amplo espectro contra doenças causadas por neisseria meningitidis |
| CA2808919C (en) * | 2005-12-22 | 2016-04-19 | Glaxosmithkline Biologicals S.A. | Streptococcus pneumoniae capsular saccharide vaccine |
| SI2097102T1 (sl) | 2006-09-07 | 2012-09-28 | Glaxosmithkline Biolog Sa | Kombinirano cepivo, ki ima zmanjšane količine antigena za poliovirus |
| CA2702871A1 (en) | 2007-10-19 | 2009-04-23 | Novartis Ag | Meningococcal vaccine formulations |
| JP2011503104A (ja) | 2007-11-09 | 2011-01-27 | カリフォルニア インスティテュート オブ テクノロジー | 免疫調節化合物ならびに関連組成物および方法 |
| CN105044337A (zh) * | 2008-02-01 | 2015-11-11 | 圣诺菲·帕斯图尔有限公司 | 用于诊断肺炎链球菌的试验 |
| DK2268618T3 (en) | 2008-03-03 | 2015-08-17 | Novartis Ag | Compounds and compositions as TLR aktivitetsmodulatorer |
| NZ593674A (en) | 2008-12-17 | 2013-03-28 | Novartis Ag | Meningococcal vaccines including hemoglobin receptor |
| EP2440245B1 (en) | 2009-06-10 | 2017-12-06 | GlaxoSmithKline Biologicals SA | Benzonaphthyridine-containing vaccines |
| AU2010288239B2 (en) | 2009-08-27 | 2014-01-16 | Novartis Ag | Adjuvant comprising aluminium, oligonucleotide and polycation |
| SG178954A1 (en) | 2009-09-02 | 2012-04-27 | Novartis Ag | Immunogenic compositions including tlr activity modulators |
| TWI445708B (zh) | 2009-09-02 | 2014-07-21 | Irm Llc | 作為ｔｌｒ活性調節劑之化合物及組合物 |
| EP2486940B1 (en) * | 2009-10-08 | 2017-10-04 | Aeon Medix Inc. | Composition comprising extracellular membrane vesicles derived from indoor air, and use thereof |
| WO2011057148A1 (en) | 2009-11-05 | 2011-05-12 | Irm Llc | Compounds and compositions as tlr-7 activity modulators |
| MX339146B (es) | 2009-12-15 | 2016-05-13 | Novartis Ag | Suspension homogenea de compuestos inmunopotenciadores y usos de los mismos. |
| JP5894083B2 (ja) * | 2009-12-22 | 2016-03-23 | サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ | 免疫原性組成物 |
| EP2547357A1 (en) | 2010-03-18 | 2013-01-23 | Novartis AG | Adjuvanted vaccines for serogroup b meningococcus |
| EP2549990A1 (en) | 2010-03-23 | 2013-01-30 | Irm Llc | Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc. |
| WO2011127302A2 (en) * | 2010-04-07 | 2011-10-13 | Yue Shen | Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems |
| US9259462B2 (en) * | 2010-09-10 | 2016-02-16 | Glaxosmithkline Biologicals Sa | Developments in meningococcal outer membrane vesicles |
| EP2707009A1 (en) | 2011-05-12 | 2014-03-19 | Novartis AG | Antipyretics to enhance tolerability of vesicle-based vaccines |
| EP2731617A4 (en) | 2011-07-12 | 2015-07-01 | Brigham & Womens Hospital | LIPID-BASED PSA COMPOSITIONS, METHOD FOR THEIR INSULATION AND USE METHOD THEREFOR |
| ES2654613T3 (es) | 2012-02-02 | 2018-02-14 | Glaxosmithkline Biologicals Sa | Promotores para una expresión aumentada de proteínas en meningococos |
| JP2015517089A (ja) | 2012-03-08 | 2015-06-18 | ノバルティス アーゲー | タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ |
| US10376573B2 (en) | 2012-06-14 | 2019-08-13 | Glaxosmithkline Biologicals Sa | Vaccines for serogroup X meningococcus |
| AU2013311702A1 (en) | 2012-09-06 | 2015-02-19 | Novartis Ag | Combination vaccines with serogroup B meningococcus and D/T/P |
| US11331335B2 (en) | 2015-06-10 | 2022-05-17 | California Institute Of Technology | Sepsis treatment and related compositions methods and systems |
| EP3337321A4 (en) | 2015-08-19 | 2019-07-17 | President and Fellows of Harvard College | LIPIDED PSA COMPOSITIONS AND METHOD |
| EP3484441A4 (en) | 2016-07-15 | 2020-03-18 | President and Fellows of Harvard College | GLYCOLIPID COMPOSITIONS AND METHOD FOR USE |
| CA3035320A1 (en) | 2016-09-02 | 2018-03-08 | Glaxosmithkline Biologicals Sa | Vaccines for neisseria gonorrhoeae |
| CA3166272A1 (en) * | 2020-10-23 | 2022-04-28 | Omvax, Inc. | Compositions and methods for vaccination against neisseria gonorrhoeae |
| GB202115077D0 (en) | 2021-10-21 | 2021-12-08 | Glaxosmithkline Biologicals Sa | Assay |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL338146A1 (en) * | 1997-07-17 | 2000-09-25 | North American Vaccine | Immunogenic complex combinations consisting of meningococcal porine of b group and h. influenzae polysaccharide |
| GB9918319D0 (en) * | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
| KR20030024811A (ko) * | 2000-07-27 | 2003-03-26 | 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 | 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신 |
-
2002
- 2002-06-13 GB GBGB0213622.4A patent/GB0213622D0/en not_active Ceased
-
2003
- 2003-06-10 CA CA002488782A patent/CA2488782A1/en not_active Abandoned
- 2003-06-10 NZ NZ560766A patent/NZ560766A/en not_active IP Right Cessation
- 2003-06-10 BR BR0311777-4A patent/BR0311777A/pt not_active IP Right Cessation
- 2003-06-10 AU AU2003236734A patent/AU2003236734A1/en not_active Abandoned
- 2003-06-10 US US10/529,064 patent/US20060110412A1/en not_active Abandoned
- 2003-06-10 KR KR1020047019991A patent/KR20050049431A/ko not_active Ceased
- 2003-06-10 MX MXPA04012568A patent/MXPA04012568A/es not_active Application Discontinuation
- 2003-06-10 WO PCT/EP2003/006094 patent/WO2003105890A2/en not_active Ceased
- 2003-06-10 JP JP2004512791A patent/JP2005531614A/ja active Pending
- 2003-06-10 CL CL200301192A patent/CL2003001192A1/es unknown
- 2003-06-10 RU RU2005100509/13A patent/RU2005100509A/ru not_active Application Discontinuation
- 2003-06-10 EP EP03735599A patent/EP1565211A2/en not_active Ceased
- 2003-06-10 CN CNB038162822A patent/CN100387298C/zh not_active Expired - Fee Related
- 2003-06-11 PE PE2003000583A patent/PE20040562A1/es not_active Application Discontinuation
- 2003-06-11 UY UY27843A patent/UY27843A1/es unknown
- 2003-06-11 AR ARP030102096A patent/AR040204A1/es not_active Application Discontinuation
-
2004
- 2004-11-25 ZA ZA200409547A patent/ZA200409547B/en unknown
- 2004-12-10 CU CU20040285A patent/CU23552A1/es active IP Right Grant
-
2005
- 2005-01-11 NO NO20050132A patent/NO20050132L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005531614A5 (enExample) | ||
| RU2378009C2 (ru) | Иммунизация против менингококков серогруппы y с помощью белков | |
| RU2005100509A (ru) | Вакцинная композиция | |
| JP5597245B2 (ja) | アジュバント添加した髄膜炎菌ｈ因子結合タンパク質 | |
| JP2005504718A5 (enExample) | ||
| JP5410498B2 (ja) | ワクチン組成物 | |
| JP2014506916A5 (enExample) | ||
| WO2005105141A3 (en) | Combined meningococcal conjugates with common carrier protein | |
| WO2007026249A3 (en) | Multiple vaccination including serogroup c meningococcus | |
| CA2634887A1 (en) | Capsular saccharide conjugate vaccines against streptococcus pneumoniae | |
| JP2005508849A5 (enExample) | ||
| JP2005526847A5 (enExample) | ||
| EP2462949A3 (en) | Meningococcal vaccine formulations | |
| WO2000062800A3 (en) | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide | |
| MA30071B1 (fr) | Vaccin | |
| JP2008526939A5 (enExample) | ||
| EP2172213A3 (en) | Injectable vaccines against multiple meningococcal serogroups | |
| JP2020523323A5 (enExample) | ||
| JP2008543908A5 (enExample) | ||
| MY180698A (en) | Immunization protocol against the 4 dengue serotypes | |
| RU2005127200A (ru) | Менингококковые вакцины для введения через слизистую оболочку | |
| WO2007111940A3 (en) | Regimens for immunisation with meningococcal conjugates | |
| JP2007533729A5 (enExample) | ||
| JP2003513935A5 (enExample) | ||
| Rodgers et al. | Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule |